Homologous and Heterologous Vaccination Regimens with mRNA and rVSV Platforms Induce Potent Immune Responses Against SFTSV Glycoprotein
Viruses · 2025
DOI: 10.3390/v17081095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Tomaz B Manzoni und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Viral Vaccines, Phlebovirus, Glycoproteins, Severe Fever with Thrombocytopenia Syndrome. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
Severe fever with thrombocytopenia syndrome virus (SFTSV) is a highly pathogenic bunyavirus with a high case-fatality ratio for which there is no approved vaccine. Studies have assessed different vaccine technologies. However, few studies have yet assessed the immunogenicity of heterologous prime-boost regimens.
Methods
Here, we compare a lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA-based vaccine encoding the SFTSV glycoproteins, Gn and Gc, to our recently described recombinant VSV SFTSV (rVSV-SFTSV) vaccine in single dose, homologous, and heterologous prime-boost regimens in mice.
Results
We show that all regimens protect from pathogenic SFTSV challenge and elicit strong long-lasting antibody responses. Furthermore, strong cellular immunity is elicited by mRNA-LNP immunizations and by heterologous immunization with an rVSV-SFTSV prime and mRNA-LNP boost. Cellular responses robustly polarized towards a type 1 response, characterized by high levels of IFNγ, TNFα, and IL-2. Immunization with mRNA led to a mixed type 1/type 2 immune response, as determined by antibody isotypes IgG1 and IgG2c. We found that homologous immunization leads to stronger antibody responses while heterologous immunization drives a slightly stronger cellular response.
Conclusions
Taken together, the vaccine platforms described here represent strong vaccine candidates for further development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT 84322, USA.
- Institute for RNA Innovation, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Acuitas Therapeutics, Vancouver, BC V6T 1Z3, Canada.
ORCID-Profile: Tomaz B Manzoni, Jonna B Westover, Philip D Hicks, Raegan J Petch, Norbert Pardi, Brian B Gowen, Paul Bates
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health (NIH)
Zitieren
APA
Manzoni, T. B., Westover, J. B., Lundgreen, K. A., Hicks, P. D., Petch, R. J., Ort, J. T., Weissman, D., Fan, S. H. Y., Hensley, S. E., Pardi, N., Gowen, B. B., & Bates, P. (2025). Homologous and Heterologous Vaccination Regimens with mRNA and rVSV Platforms Induce Potent Immune Responses Against SFTSV Glycoprotein. Viruses. https://doi.org/10.3390/v17081095
Vancouver
Manzoni TB, Westover JB, Lundgreen KA, Hicks PD, Petch RJ, Ort JT, et al. Homologous and Heterologous Vaccination Regimens with mRNA and rVSV Platforms Induce Potent Immune Responses Against SFTSV Glycoprotein. Viruses. 2025. doi:10.3390/v17081095
BibTeX
@article{Manzoni2025,
author = {Manzoni, Tomaz B and Westover, Jonna B and Lundgreen, Kendall A and Hicks, Philip D and Petch, Raegan J and Ort, Jordan T and Weissman, Drew and Fan, Steven H Y and Hensley, Scott E and Pardi, Norbert and Gowen, Brian B and Bates, Paul},
title = {Homologous and Heterologous Vaccination Regimens with mRNA and rVSV Platforms Induce Potent Immune Responses Against SFTSV Glycoprotein},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17081095}
}
EUVIMED